Your Search Returned 32 tagged news reports
A proxy war with its top shareholder is building up the pressure on Vivus Inc to quickly ramp up the sales of its diet drug, Qsymia , as skepticism grows among investors and analysts about the medicine's potential. First Manhattan Co, with a 9.9
Monday were AXT Inc, MediciNova, Amyris, Universal Display Corp and TGC Industries Inc.
The higher costs of selling Qsymia, along with associated general and administrative expenses, pushed up the company's loss. This latest loss pushed Vivus' accumulated deficit -- how much money it has lost or written off since it started -- to $486,
Inc, Arena Pharmaceuticals, and the Weight-loss Craze Meena is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited. According to a Centers for Disease Control study earlier
Food and Drug Administration in July is now available for obese and at-risk overweight patients. The oral medication Qsymia can only be obtained with a doctor's prescription. Qsymia (pronounced kyoo-SIM-ee-uh) is the second diet drug approved this
Former Bergen Co. drug marker lands obesity drug contract * Parsippany -based PDI will market Vivus' obesity medication. A New Jersey company that markets drugs to the physicians who prescribe them stands to benefit from the government's approval
The Food and Drug Administration on Tuesday approved a new weight loss drug from Vivus Inc. that many doctors consider the most effective therapy in a new generation of anti-obesity pills designed to help patients safely shed pounds.
File this under getting ahead of the curve.' Anticipating that the FDA will approve the Vivus diet pill, at least one law firm is already trolling for possible clients. The Internet ad by the Van Wey law firm actually does not invite anyone to pick
Food and Drug Administration has approved Stendra, or avanafil, tablets for the treatment of erectile dysfunction in men, officials said. Peter Tam, president of the biopharmaceutical company Vivus, said the approval is the first for nearly a decade
Md. (AP) — A panel of advisers to the Food and Drug Administration overwhelmingly backed approval for a highly anticipated anti-obesity pill called Qnexa, a drug which the FDA previously rejected due to safety concerns. The FDA